<DOC>
	<DOCNO>NCT01893567</DOCNO>
	<brief_summary>The aim study investigate utility technological base rating scale assess improvement plaque psoriasis Clobex spray treatment .</brief_summary>
	<brief_title>Subject Reported Target-lesion Numeric Rating Scale Evaluation Subjects With Plaque Psoriasis Treated With ClobexÂ® ( Clobetasol Propionate ) Spray 0.05 %</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Erythema Multiforme</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subjects 18 year age old . Subjects board certify dermatologist clinical diagnosis active moderate severe psoriasis lesion affect 20 % body surface area baseline visit , opinion investigator , otherwise good candidate treatment clobetasol propionate 0.05 % spray . Subjects target lesion least 1 cm x 1 cm Subjects agree photograph visit Subjects condition presentation may , opinion investigator , may put subject risk , may confound study result , may interfere participation study . Subjects know allergy ingredient list test article label surgical ink . Subjects pregnant breastfeeding , plan become pregnant breast feed course trial . Subjects relatives investigator , relative study staff Galderma employee . Subjects participate investigational study within 30 day enrollment ; participate biologic investigational study within 90 day enrollment , subject plan participate interventional clinical research study enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>